logo

Arqule Inc. (ARQL)



Trade ARQL now with
  Date
  Headline
8/1/2018 7:04:27 AM ArQule Q2 EPS $0.05 Vs Loss $0.10 Last Year
7/11/2018 7:00:53 AM ArQule Prices Public Offering Of 11 Mln Common Shares At $5.50 Per Share
7/10/2018 4:13:37 PM ArQule Commences Proposed Public Offering Of Common Stock
6/15/2018 7:00:49 AM ArQule Presents Results From Ongoing Phase 1 Dose Escalation Study Of Reversible BTK Inhibitor, ARQ 531
6/7/2018 7:00:42 AM ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531
5/24/2018 7:06:22 AM ArQule Announces Two Key Appointments
5/7/2018 7:01:58 AM ArQule Q1 Net Loss $6.53 Mln Or $0.07/Shr Vs Loss Of $7.58 Mln Or $0.11/Shr Last Eyar
4/17/2018 7:01:24 AM ArQule And Basilea Enter License Deal For Derazantinib In The US, EU, Japan And Rest Of World Excluding Greater China
4/17/2018 1:18:10 AM Basilea Pharmaceutica Enters Into License Deal With ArQule For Oncology Drug Candidate ARQ 087